Target intelligence / Profile preview

High mobility group nucleosomal binding domain 2 pseudogene 17 (HMGN2P17)

Target
HMGN2P17
Molecular classification
Pseudogene, Other
01

Overview

High mobility group nucleosomal binding domain 2 pseudogene 17 (HMGN2P17) is a human pseudogene, meaning it is a DNA sequence that shares high sequence homology with the functional HMGN2 gene but does not produce a functional protein product. According to the HUGO Gene Nomenclature Committee definition, pseudogenes like HMGN2P17 are typically transcriptionally inactive, although emerging research suggests that some pseudogenes may have regulatory roles at the RNA level. There is little to no direct evidence that HMGN2P17 itself has a characterized biological function, is involved in cell signaling or disease as an active molecular entity, or serves as a therapeutic target. While some pseudogenes have been implicated as competitive endogenous RNAs or regulatory molecules in cancer and other diseases, there is no evidence that HMGN2P17 is a validated therapeutic or diagnostic target. HMGN2P17 may appear in databases primarily as a genomic locus or reference sequence.

Other names
HMGN2P17
02

Mechanism of action

None known; pseudogenes generally do not encode functional proteins, and HMGN2P17 is not a characterized molecular target

03

Biological functions

Other
04

Disease associations

Cancer (notably, pseudogenes have been connected in general to various cancer processes, but there is no disease association specifically characterized for HMGN2P17, though GeneCards notes an association with prostate cancer)

Beyond the preview

Go deeper on High mobility group nucleosomal binding domain 2 pseudogene 17 (HMGN2P17).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on High mobility group nucleosomal binding domain 2 pseudogene 17 (HMGN2P17).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call